Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure

Inclusion Criteria: * Age: 18 years or older. * Informed Consent: Willing and able to sign the informed consent form. * Stable Chronic HF: A clinical diagnosis of chronic heart failure considered stable by the patient's cardiologist/physician or another experienced clinician for at least one month prior to randomization. * Current Diuretic Therapy: Receiving an oral dose of 20 mg to 80 mg daily of furosemide, or 10 mg to 40 mg daily dose of torsemide, or 1 mg to 4 mg daily dose of bumetanide, for about 30 days prior to randomization. * Stable HF Medications: No anticipated changes in HF medications during the study period. * Female Participants: Premenopausal women of childbearing potential must have a negative pregnancy test prior to study initiation and agree to use effective contraceptive methods throughout the study period. Exclusion Criteria: * Other Diuretics: Requirement for a diuretic other than furosemide, bumetanide, or torsemide (except for spironolactone, eplerenone, finerenone, or SGLT2 inhibitors) at randomization or during the study. * Recent Cardiovascular Events: Myocardial infarction, stroke, transient ischemic attack, acute kidney injury, or acute HF requiring hospitalization within 30 days prior to randomization. * Severe Lung Disease: Severe or symptomatic lung disease or respiratory symptoms distinct from HF. * Urinary Issues: History of urinary incontinence, or inability to empty the bladder. * Uncontrolled Comorbidities: Uncontrolled diabetes mellit…